Vistagen Cuts Quarterly Loss to $10.7M but Cash Only Funds Operations Into 2027
VTGN is trading near its 52-week low of $0.164 (10% above the low).
Summary
Vistagen reported a fiscal Q2 2027 net loss of $10.7 million, down from $19.4 million a year earlier, as R&D expense fell to $6.6 million from $15.9 million after the PALISADE-3 and PALISADE-4 open-label extensions wrapped up, on revenue of $138,000. The problem is the balance sheet: cash, equivalents and marketable securities totaled $20.0 million at September 30, enough to fund operations into 2027 but explicitly not for more than a year from now. That follows the 31% workforce cut disclosed October 30 and the going-concern doubt flagged in the last 10-Q, so the runway question is now the dominant issue. On the pipeline, management says the November 9 FDA Type C meeting gave constructive feedback on using LSAS as the primary endpoint and on pursuing overall rather than only acute SAD treatment, and it added Douglas Williamson to the board. With shares at roughly $0.18 and Nasdaq's compliance deadline set for February 2027, the next capital raise is the event that matters.
At the time of this announcement, VTGN was trading at $0.18 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8M. The 52-week trading range was $0.16 to $5.14. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.